Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Mycophenolate mofetil in lupus nephritis].

L Alvarez1, F Rivera, C M Gil

  • 1Servicio de Nefrología, Hospital General Universitario de Alicante.

Nefrologia : Publicacion Oficial De La Sociedad Espanola Nefrologia
|May 4, 2002
PubMed
Summary

Mycophenolate mofetil effectively treats relapsing lupus nephritis in patients unresponsive to standard therapies. This immunosuppressant offers a safe alternative, significantly reducing proteinuria and steroid dependence.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dose optimization of immune checkpoint inhibitors for gastrointestinal malignancies.

ESMO gastrointestinal oncology·2026
Same author

Clinical validation of liquid biopsy-RECIST (LB-RECIST) in metastatic colorectal cancer (mCRC) patients: findings from the PLATFORM-B study.

ESMO open·2025
Same author

Promoting large multinational academic clinical trials for gastrointestinal cancers in Europe: the ENGIC (European Network for GI Cancers) initiative.

ESMO open·2025
Same author

Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Italian Club of Osteosynthesis (CIO): Current Trends in Orthopaedic Trauma Care.

Injury·2024
Same author

Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials.

Clinical colorectal cancer·2023

Area of Science:

  • Nephrology
  • Immunology
  • Pharmacology

Background:

  • Severe lupus nephritis often requires combination therapy with steroids and cytotoxic drugs.
  • Intravenous cyclophosphamide effectively induces remission but alternatives are needed for refractory or relapsing cases.

Observation:

  • Six patients with severe lupus nephritis who relapsed after initial remission were treated with mycophenolate mofetil (1000-2000 mg/day).
  • Patients received treatment for 6 to 24 months.
  • All patients achieved partial or complete remission, with significant reductions in proteinuria and steroid dosage.

Findings:

  • Mycophenolate mofetil treatment led to remission in all patients, with no treatment failures.
  • Significant decreases in proteinuria (protein/creatinine ratio) and daily steroid dose were observed.

Related Experiment Videos

  • Autoantibodies (ANA and anti-DNA) decreased, while renal function markers remained stable.
  • Common side effects included nausea and abdominal discomfort, which resolved without treatment cessation.

    • Implications:

    • Mycophenolate mofetil is a safe and effective therapeutic option for severe, relapsing lupus nephritis.
    • This drug can help reduce steroid dependency and improve patient outcomes in challenging cases.
    • Further research into long-term efficacy and optimal dosing in lupus nephritis is warranted.